What is the Rebiotix MRT™ Drug Platform?
The influence of human gut microbiota on our health is an exciting and expanding frontier of research. New discoveries are published frequently underscoring the power and influence of these tiny organisms and their ecosystems over our every-day lives. Understanding this power, and how it can be harnessed to restore health or prevent disease, has been the guiding force for Rebiotix since its founding in 2011.
Built on a strong foundation of rigorous testing and scientific evidence, Rebiotix Inc., a Ferring Company, has established a microbiota-based drug platform to use in the never-ending battle against disease progression and recurrence. Known as the MRT™ drug platform, Rebiotix uses controlled manufacturing processes and quality control parameters to assess the impact of human-derived microbiota therapies on health and disease.
The first formulation of the platform, RBX2660, is currently in clinical trials for the prevention of recurrent Clostridium difficile (C. diff) infection. The clinical trials are conducted under the U.S. FDA’s Investigational New Drug (IND) application with the purpose of studying safety, efficacy, and impact of microbiota-based therapeutics’ on the prevention of C. diff recurrence. The second formulation in development, RBX7455, is the first of its kind non-frozen, room-temperature stable, orally delivered microbiota-based product. RBX2660 and RBX7455 will serve as critical facets of the MRT drug platform, paving the way for further research and product development. Currently, the MRT drug platform is the most clinically advanced program in the world.